Fecal microbiota transfer not checked

MaaT Pharma · MaaT013

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
1 active
4 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota”In the company’s words, NCT04769895 on ClinicalTrials.gov
Tested for
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD, Fecal Microbiota Transplantation
Main trialPhase 3
“MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard 2020), therefore warrant being tested as salvage therapy in steroid and JAK inhibitors-resistant GI-aGvHD patients. Given the absence of an approved 3rd line strategy or 2nd line strategy in ruxolitinib intolerant patients and the extremely poor prognosis of these patients, who are mostly left with no viable therapeutic option, a single-arm open-label design was proposed.”In the company’s words, NCT04769895 on ClinicalTrials.gov
Other names
MaaT013

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Unknown Nov 2024 MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Phase 2Completed 25 Feb 2020 Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
Phase 2Ended not given PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitors
Phase 2Authorised not given A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Fecal microbiota transfer

Following is part of Solo: you see every change to Fecal microbiota transfer the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in